Dren Bio Raises $350M in Private Financing to Advance Rare Blood Cancer Treatment Toward Commercialization

San Carlos, CA, October 29, 2026 (Business Wire) -- Dren Bio, a privately held, clinical-stage biotechnology company developing antibody-based therapies for cancer, autoimmune, and other serious diseases, has closed an oversubscribed $350 million private financing round co-led by Juvia Group and Lightspeed Venture Partners. The financing also includes participation from new investors Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management, and OrbiMed, alongside existing investors including 8VC, SR One, Taiho Ventures, Mission BioCapital, HBM Healthcare Investments, BVF Partners, Aisling Capital, and ArrowMark Partners.

Read full article here.